St George Hospital

Running trials

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Genmab· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Phase 3· Takeda· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

• Recruiting

  The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

  NCT06058585· Phase 3· The George Institute· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

• Recruiting

  A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  NCT06064877· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Helsinki University Central Hospital· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

  NCT05393791· Phase 2· Leiden University Medical Center· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· University Medical Center Groningen· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· University College, London· Source

• Active, not recruiting

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study of BGB-11417 in Participants With Myeloid Malignancies

  NCT04771130· Phase 1/2· BeOne Medicines· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

  NCT04623541· Phase 1/2· Genmab· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

  NCT04419402· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

  NCT03974022· Phase 1/2· Dizal Pharmaceuticals· Source

• Recruiting

  The EXCEL Registry of Patients Requiring ECMO

  NCT03793257· Australian and New Zealand Intensive Care Research Centre· Source

• Active, not recruiting

  First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037· Phase 1/2· Genmab· Source

• Active, not recruiting

  Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

  NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source

• Active, not recruiting

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source

• Active, not recruiting

  Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

  NCT02446405· Phase 3· University of Sydney· Source

• Active, not recruiting

  Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

  NCT02446444· Phase 3· University of Sydney· Source

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source

• Active, not recruiting

  Radiotherapy - Adjuvant Versus Early Salvage

  NCT00860652· Trans Tasman Radiation Oncology Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

  NCT06331624· Phase 2· GRI Bio Operations, Inc.· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· BeiGene· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Australasian Gastro-Intestinal Trials Group· Source

• Completed

  Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953· Phase 3· The George Institute· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Completed

  A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

  NCT03497767· Phase 2· Trans Tasman Radiation Oncology Group· Source

• Completed

  ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

  NCT03685448· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

• Completed

  A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

  NCT03456063· Phase 3· Hoffmann-La Roche· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Hoffmann-La Roche· Source

• Completed

  SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

  NCT02439775· Medtronic Vascular· Source

• Completed

  Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

  NCT01208766· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Epidermolysis bullosa14 works · 0 trials